Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
01 août 2024 16h30 HE
|
Interpace Biosciences, Inc.
●Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ●Q2 Test volume up 12% year-over-year to record levels ●Q2 Cash collections of $11.0M; a $0.7M and 7% increase year-over-year ●Q2...
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
09 mai 2024 16h01 HE
|
Interpace Biosciences, Inc.
●Q1 Revenue of $10.3 million; a 4% increase year-over-year ●Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc....
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
07 mars 2024 08h00 HE
|
Interpace Biosciences, Inc.
●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and...
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
09 août 2023 12h30 HE
|
Interpace Biosciences, Inc.
●Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ●Q2 Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year...
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results
12 mai 2023 16h05 HE
|
Interpace Biosciences, Inc.
●Q1 Revenue of $9.8 million; a 24% increase year-over-year; highest quarter in history ●Q1 Test volume up nearly 20% year over year to record levels ●Q1 41.9 million covered lives added, resulting...
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
27 mars 2023 16h05 HE
|
Interpace Biosciences, Inc.
●Q4 Revenue of $8.3 million ●Cash and Cash Equivalents total $4.8 million as of December 31, 2022 PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or...
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern
14 nov. 2022 16h41 HE
|
Interpace Biosciences, Inc.
Q3 Revenue of $8.2 million up 2% versus Prior YearQ3 Adjusted EBITDA PositiveCash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE)...
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
15 août 2022 16h05 HE
|
Interpace Biosciences, Inc.
●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding...